Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q4 2017 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
JAZZ PHARMACEUTICALS PLC | 8 | Q3 2023 | 7.2% |
TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 5.7% |
IMMUNOVANT INC | 8 | Q3 2023 | 7.2% |
BICYCLE THERAPEUTICS PLC | 8 | Q3 2023 | 5.2% |
BEAM THERAPEUTICS INC | 8 | Q3 2023 | 3.9% |
4D MOLECULAR THERAPEUTICS IN | 8 | Q3 2023 | 2.9% |
REPARE THERAPEUTICS INC | 8 | Q3 2023 | 3.1% |
VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 2.2% |
DYNE THERAPEUTICS INC | 8 | Q3 2023 | 2.2% |
SILENCE THERAPEUTICS PLC | 8 | Q3 2023 | 1.6% |
View Deep Track Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Orchard Therapeutics plc | March 20, 2023 | 19,125,150 | 10.0% |
ARDELYX, INC.Sold out | February 14, 2023 | 0 | 0.0% |
ASSEMBLY BIOSCIENCES, INC. | February 14, 2023 | 1,833,437 | 3.8% |
Aurinia Pharmaceuticals Inc. | February 14, 2023 | 324,238 | 0.2% |
CHINOOK THERAPEUTICS, INC. | February 14, 2023 | 3,000,000 | 4.7% |
Forma Therapeutics Holdings, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Global Blood Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
HOOKIPA Pharma Inc. | February 14, 2023 | 1,240,369 | 2.4% |
KalVista Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Keros Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View Deep Track Capital, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
4 | 2024-05-13 |
SC 13G | 2024-05-10 |
SC 13G | 2024-04-26 |
SC 13G | 2024-04-26 |
SC 13G/A | 2024-04-22 |
SC 13G | 2024-04-12 |
SC 13G | 2024-04-05 |
SC 13G | 2024-03-22 |
SC 13G | 2024-03-22 |
View Deep Track Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.